{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T19:10:15Z","timestamp":1654197015535},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,1,29]],"date-time":"2016-01-29T00:00:00Z","timestamp":1454025600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00063-015-0138-4","type":"journal-article","created":{"date-parts":[[2016,1,29]],"date-time":"2016-01-29T07:29:55Z","timestamp":1454052595000},"page":"241-252","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapie mit Blutprodukten"],"prefix":"10.1007","volume":"111","author":[{"given":"S.","family":"Petros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,29]]},"reference":[{"key":"138_CR1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199902113400601","volume":"340","author":"PC Hebert","year":"1999","unstructured":"Hebert PC, Wells G, Blajchman MA et\u00a0al (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N\u00a0Engl J Med 340:409\u2013417","journal-title":"N\u00a0Engl J Med"},{"key":"138_CR2","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJMoa1406617","volume":"371","author":"LB Holst","year":"2014","unstructured":"Holst LB, Haase N, Wetterslev J et\u00a0al (2014) Lower versus higher hemoglobin threshold for transfusion in septic shock. N\u00a0Engl J Med 371:1381\u20131391","journal-title":"N\u00a0Engl J Med"},{"key":"138_CR3","unstructured":"Querschnitts-Leitlinien (B\u00c4K) zur Therapie mit Blutkomponenten und Plasmaderivaten. 4.\u00a0\u00fcberarbeitete und aktualisierte Auflage. http:\/\/www.bundesaerztekammer.de\/fileadmin\/user_upload\/downloads\/QLL_Haemotherapie_2014.pdf . Zugegriffen: 16.\u00a0Juli 2015"},{"key":"138_CR4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.7326\/0003-4819-157-1-201206190-00429","volume":"157","author":"JL Carson","year":"2012","unstructured":"Carson JL, Grossman BJ, Kleinman S et\u00a0al (2012) Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 157:49\u201358","journal-title":"Ann Intern Med"},{"key":"138_CR5","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1046\/j.1537-2995.1999.39101070.x","volume":"39","author":"AW Bracey","year":"1999","unstructured":"Bracey AW, Radovancevic R, Riggs SA et\u00a0al (1999) Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion 39:1070\u20131077","journal-title":"Transfusion"},{"key":"138_CR6","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1056\/NEJMoa1012452","volume":"365","author":"JL Carson","year":"2011","unstructured":"Carson JL, Terrin ML, Noveck H et\u00a0al (2011) Liberal or restrictive transfusion in high-risk patients after hip surgery. N\u00a0Engl J Med 365:2453\u20132462","journal-title":"N\u00a0Engl J Med"},{"key":"138_CR7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.transci.2004.06.002","volume":"31","author":"JF Hardy","year":"2004","unstructured":"Hardy JF (2004) Current status of transfusion triggers for red blood cell concentrates. Transfus Apher Sci 31:55\u201366","journal-title":"Transfus Apher Sci"},{"key":"138_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1211801","volume":"368","author":"C Villanueva","year":"2013","unstructured":"Villanueva C, Colomo A, Bosch A et\u00a0al (2013) Transfusion strategies for acute upper gastrointestinal bleeding. N\u00a0Engl J Med 368:11\u201321","journal-title":"N\u00a0Engl J Med"},{"key":"138_CR9","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood.V66.5.1105.1105","volume":"66","author":"SR Hanson","year":"1985","unstructured":"Hanson SR, Slichter SJ (1985) Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 66:1105\u20131109","journal-title":"Blood"},{"key":"138_CR10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tmrv.2004.03.003","volume":"18","author":"SJ Slichter","year":"2004","unstructured":"Slichter SJ (2004) Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 18:153\u2013167","journal-title":"Transfus Med Rev"},{"key":"138_CR11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1182\/asheducation-2007.1.172","volume":"2007","author":"SJ Slichter","year":"2007","unstructured":"Slichter SJ (2007) Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program 2007:172\u2013178","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"138_CR12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M14-1589","volume":"162","author":"RM Kaufman","year":"2015","unstructured":"Kaufman RM, Djulbegovic B, Gernsheimer T et\u00a0al (2015) Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 162:205\u2013213","journal-title":"Ann Intern Med"},{"key":"138_CR13","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/j.1537-2995.2005.04157.x","volume":"45","author":"B Diedrich","year":"2005","unstructured":"Diedrich B, Remberger M, Shanwell A et\u00a0al (2005) A prospective randomized trial of a prophylactic platelet transfusion trigger of 10\u2009\u00d7\u200910(9) per\u00a0L versus 30\u2009\u00d7\u200910(9) per\u00a0L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion 45:1064\u20131072","journal-title":"Transfusion"},{"key":"138_CR14","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.1997.15.3.1143","volume":"15","author":"KD Heckman","year":"1997","unstructured":"Heckman KD, Weiner GJ, Davis CS et\u00a0al (1997) Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000\/microL versus 20,000\/microL. J\u00a0Clin Oncol 15:1143\u20131149","journal-title":"J\u00a0Clin Oncol"},{"key":"138_CR15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1053\/bbmt.2002.v8.pm12434952","volume":"8","author":"MS Zumberg","year":"2002","unstructured":"Zumberg MS, Del Rosario ML, Nejame CF et\u00a0al (2002) A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000\/L versus 20,000\/microL trigger. Biol Blood Marrow Transplant 8:569\u2013576","journal-title":"Biol Blood Marrow Transplant"},{"key":"138_CR16","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/j.1537-2995.2010.02630.x","volume":"50","author":"MH Murad","year":"2010","unstructured":"Murad MH, Stubbs JR, Gandhi MJ et\u00a0al (2010) The effect of plasma transfusion on morbidity and mortality: a systematic review and meta-analysis. Transfusion 50:1370\u20131383","journal-title":"Transfusion"},{"key":"138_CR17","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1537-2995.2010.02632.x","volume":"50","author":"JD Roback","year":"2010","unstructured":"Roback JD, Caldwell S, Carson J et\u00a0al (2010) Evidence-based practice guidelines for plasma transfusion. Transfusion 50:1227\u20131239","journal-title":"Transfusion"},{"key":"138_CR18","doi-asserted-by":"crossref","unstructured":"De Pietri L, Bianchini M, Montalti R et\u00a0al (2015) Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy. A randomized controlled trial. Hepatology (im Druck). doi: 10.1002\/hep.28148","DOI":"10.1002\/hep.28148"},{"key":"138_CR19","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","volume":"128","author":"R Sarode","year":"2013","unstructured":"Sarode R, Milling TJ Jr, Refaai MA et\u00a0al (2013) Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin\u00a0K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase\u00a0IIIb study. Circulation 128:1234\u20131243","journal-title":"Circulation"},{"key":"138_CR20","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(14)61685-8","volume":"385","author":"JN Goldstein","year":"2015","unstructured":"Goldstein JN, Refaai MA, Milling TJ Jr et\u00a0al (2015) Four-factor prothrombin complex concentrate versus plasma for rapid vitamin\u00a0K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase\u00a03b, open-label, non-inferiority, randomised trial. Lancet 385:2077\u20132087","journal-title":"Lancet"},{"key":"138_CR21","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.injury.2010.12.015","volume":"42","author":"U Nienaber","year":"2011","unstructured":"Nienaber U, Innerhofer P, Westermann I et\u00a0al (2011) The impact of fresh frozen plasma vs coagulation factor concentrates on morbidity and mortality in trauma-associated haemorrhage and massive transfusion. Injury 42:697\u2013701","journal-title":"Injury"},{"key":"138_CR22","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1111\/trf.13191","volume":"55","author":"MA Refaai","year":"2015","unstructured":"Refaai MA, Goldstein JN, Lee ML et\u00a0al (2015) Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin\u00a0K antagonist reversal. Transfusion 55:2722\u20132729","journal-title":"Transfusion"},{"key":"138_CR23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.annemergmed.2015.04.036","volume":"67","author":"TJ Milling Jr","year":"2016","unstructured":"Milling TJ Jr, Refaai MA, Goldstein JN et\u00a0al (2016) Thromboembolic events after vitamin\u00a0K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies. Ann Emerg Med. 67:96\u2013105.e5. doi: 10.1016\/j.annemergmed.2015.04.036","journal-title":"Ann Emerg Med"},{"key":"138_CR24","first-page":"360","volume":"81","author":"ST Hiippala","year":"1995","unstructured":"Hiippala ST, Myllyla GJ, Vahtera EM (1995) Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 81:360\u2013365","journal-title":"Anesth Analg"},{"key":"138_CR25","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1365-2516.2008.01831.x","volume":"14","author":"SS Acharya","year":"2008","unstructured":"Acharya SS, Dimichele DM (2008) Rare inherited disorders of fibrinogen. Haemophilia 14:1151\u20131158","journal-title":"Haemophilia"},{"key":"138_CR26","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/cc12685","volume":"17","author":"DR Spahn","year":"2013","unstructured":"Spahn DR, Bouillon B, Cerny V et\u00a0al (2013) Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 17:R76","journal-title":"Crit Care"},{"key":"138_CR27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/ALN.0b013e3182715d4d","volume":"118","author":"N Rahe-Meyer","year":"2013","unstructured":"Rahe-Meyer N, Solomon C, Hanke A et\u00a0al (2013) Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 118:40\u201350","journal-title":"Anesthesiology"},{"key":"138_CR28","doi-asserted-by":"crossref","first-page":"e002066","DOI":"10.1161\/JAHA.115.002066","volume":"4","author":"M Ranucci","year":"2015","unstructured":"Ranucci M, Baryshnikova E, Crapelli GB et\u00a0al (2015) Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J\u00a0Am Heart Assoc 4:e002066","journal-title":"J\u00a0Am Heart Assoc"},{"key":"138_CR29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1160\/TH14-07-0625","volume":"113","author":"G Dickneite","year":"2015","unstructured":"Dickneite G, Herwald H, Korte W et\u00a0al (2015) Coagulation factor\u00a0XIII: a multifunctional transglutaminase with clinical potential in a range of conditions. Thromb Haemost 113:686\u2013697","journal-title":"Thromb Haemost"},{"key":"138_CR30","first-page":"803","volume":"55","author":"Y Mishima","year":"1984","unstructured":"Mishima Y, Nagao F, Ishibiki K et\u00a0al (1984) [Factor\u00a0XIII in the treatment of postoperative refractory wound-healing disorders. Results of a controlled study]. Chirurg 55:803\u2013808","journal-title":"Chirurg"},{"key":"138_CR31","first-page":"999","volume":"37","author":"N Bregenzer","year":"1999","unstructured":"Bregenzer N, Caesar I, Andus T et\u00a0al (1999) Lack of clinical efficacy of additional factor\u00a0XIII treatment in patients with steroid refractory colitis. The Factor\u00a0XIII Study Group. Z\u00a0Gastroenterol 37:999\u20131004","journal-title":"Z\u00a0Gastroenterol"},{"key":"138_CR32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/ALN.0b013e318194b21e","volume":"110","author":"WC Korte","year":"2009","unstructured":"Korte WC, Szadkowski C, Gahler A et\u00a0al (2009) Factor\u00a0XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 110:239\u2013245","journal-title":"Anesthesiology"},{"key":"138_CR33","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1055\/s-2008-1070225","volume":"107","author":"H Rasche","year":"1982","unstructured":"Rasche H, Haghou F, Gaus W et\u00a0al (1982) [Blood clotting factor\u00a0XIII substitution in acute leukaemia: result of a randomized and controlled study]. Dtsch Med Wochenschr 107:1882\u20131886","journal-title":"Dtsch Med Wochenschr"},{"key":"138_CR34","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2141.1997.4463256.x","volume":"99","author":"DM Monroe","year":"1997","unstructured":"Monroe DM, Hoffman M, Oliver JA et\u00a0al (1997) Platelet activity of high-dose factor\u00a0VIIa is independent of tissue factor. Br J Haematol 99:542\u2013547","journal-title":"Br J Haematol"},{"key":"138_CR35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(03)12268-4","volume":"361","author":"PW Friederich","year":"2003","unstructured":"Friederich PW, Henny CP, Messelink EJ et\u00a0al (2003) Effect of recombinant activated factor\u00a0VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 361:201\u2013205","journal-title":"Lancet"},{"key":"138_CR36","first-page":"8","volume":"59","author":"KD Boffard","year":"2005","unstructured":"Boffard KD, Riou B, Warren B et\u00a0al (2005) Recombinant factor\u00a0VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J\u00a0Trauma 59:8\u201315","journal-title":"J\u00a0Trauma"},{"key":"138_CR37","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/lt.20470","volume":"11","author":"JP Lodge","year":"2005","unstructured":"Lodge JP, Jonas S, Jones RM et\u00a0al (2005) Efficacy and safety of repeated perioperative doses of recombinant factor\u00a0VIIa in liver transplantation. Liver Transpl 11:973\u2013979","journal-title":"Liver Transpl"},{"key":"138_CR38","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/bja\/aei102","volume":"94","author":"R Raobaikady","year":"2005","unstructured":"Raobaikady R, Redman J, Ball JA et\u00a0al (2005) Use of activated recombinant coagulation factor\u00a0VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth 94:586\u2013591","journal-title":"Br J Anaesth"},{"key":"138_CR39","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/j.1538-7836.2005.01523.x","volume":"3","author":"M Pihusch","year":"2005","unstructured":"Pihusch M, Bacigalupo A, Szer J et\u00a0al (2005) Recombinant activated factor\u00a0VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J\u00a0Thromb Haemost 3:1935\u20131944","journal-title":"J\u00a0Thromb Haemost"},{"key":"138_CR40","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/hep.22216","volume":"47","author":"J Bosch","year":"2008","unstructured":"Bosch J, Thabut D, Albillos A et\u00a0al (2008) Recombinant factor\u00a0VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology 47:1604\u20131614","journal-title":"Hepatology"},{"key":"138_CR41","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa0707534","volume":"358","author":"SA Mayer","year":"2008","unstructured":"Mayer SA, Brun NC, Begtrup K et\u00a0al (2008) Efficacy and safety of recombinant activated factor\u00a0VII for acute intracerebral hemorrhage. N\u00a0Engl J Med 358:2127\u20132137","journal-title":"N\u00a0Engl J Med"},{"key":"138_CR42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jama.295.3.293","volume":"295","author":"KA O\u2019Connell","year":"2006","unstructured":"O\u2019Connell KA, Wood JJ, Wise RP et\u00a0al (2006) Thromboembolic adverse events after use of recombinant human coagulation factor\u00a0VIIa. JAMA 295:293\u2013298","journal-title":"JAMA"},{"key":"138_CR43","doi-asserted-by":"crossref","first-page":"R120","DOI":"10.1186\/cc5026","volume":"10","author":"JL Vincent","year":"2006","unstructured":"Vincent JL, Rossaint R, Riou B et\u00a0al (2006) Recommendations on the use of recombinant activated factor\u00a0VII as an adjunctive treatment for massive bleeding \u2013 a European perspective. Crit Care 10:R120","journal-title":"Crit Care"},{"key":"138_CR44","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1001\/jama.286.15.1869","volume":"286","author":"BL Warren","year":"2001","unstructured":"Warren BL, Eid A, Singer P et\u00a0al (2001) Caring for the critically ill patient. High-dose antithrombin\u00a0III in severe sepsis: a randomized controlled trial. JAMA 286:1869\u20131878","journal-title":"JAMA"},{"key":"138_CR45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1538-7836.2005.01697.x","volume":"4","author":"J Kienast","year":"2006","unstructured":"Kienast J, Juers M, Wiedermann CJ et\u00a0al (2006) Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J\u00a0Thromb Haemost 4:90\u201397","journal-title":"J\u00a0Thromb Haemost"},{"key":"138_CR46","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa040232","volume":"350","author":"S Finfer","year":"2004","unstructured":"Finfer S, Bellomo R, Boyce N et\u00a0al (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N\u00a0Engl J Med 350:2247\u20132256","journal-title":"N\u00a0Engl J Med"},{"key":"138_CR47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","volume":"39","author":"RP Dellinger","year":"2013","unstructured":"Dellinger RP, Levy MM, Rhodes A et\u00a0al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165\u2013228","journal-title":"Intensive Care Med"},{"key":"138_CR48","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa1305727","volume":"370","author":"P Caironi","year":"2014","unstructured":"Caironi P, Tognoni G, Masson S et\u00a0al (2014) Albumin replacement in patients with severe sepsis or septic shock. N\u00a0Engl J Med 370:1412\u20131421","journal-title":"N\u00a0Engl J Med"},{"key":"138_CR49","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","volume":"53","author":"P Gin\u00e8s","year":"2010","unstructured":"Gin\u00e8s P, Angeli P, Lenz K et\u00a0al (2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J\u00a0Hepatol 53:397\u2013417","journal-title":"J\u00a0Hepatol"},{"key":"138_CR50","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","volume":"341","author":"P Sort","year":"1999","unstructured":"Sort P, Navasa M, Arroyo V et\u00a0al (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N\u00a0Engl J Med 341:403\u2013409","journal-title":"N\u00a0Engl J Med"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-015-0138-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00063-015-0138-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-015-0138-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T18:52:11Z","timestamp":1654195931000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00063-015-0138-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,29]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["138"],"URL":"https:\/\/doi.org\/10.1007\/s00063-015-0138-4","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,29]]}}}